ABUS
Arbutus Biopharma Corp
4.90$
-0.6%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +65.8% | -94.0% | +613.3% | -44.9% | +1.9% | +15.0% | +58.9% | +255.1% | -53.5% | -66.0% | +128.2% | |
| – | +33.1% | +19.0% | +2.3% | -7.7% | -0.5% | -17.6% | -96.3% | -18.6% | +5,064.7% | -98.1% | -73.7% | |
| – | – | – | – | – | – | – | – | +255.1% | -53.5% | -66.0% | +122.3% | |
| – | +33.1% | +19.0% | +2.3% | -7.7% | -0.5% | -14.3% | +32.8% | +28.9% | -12.7% | -26.7% | -53.3% | |
| – | +203.9% | +49.0% | -59.1% | -0.6% | +10.8% | -16.3% | +15.4% | +4.1% | +26.0% | -1.6% | -28.1% | |
| – | +63.9% | +29.6% | -20.6% | -5.8% | +21.3% | -81.3% | +390.2% | +23.6% | -7.9% | -14.3% | -50.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -21.0% | +106.4% | -81.2% | -23.4% | +954.0% | +90.3% | -28.8% | -39.6% | -73.4% | -70.2% | -29.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -16,285.0% | – | – | – | – | – | -24.7% | +302.5% | -100.0% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.